5Nunez M, Peacock JE Jr, Chin R Jr. Pulmonary Clyptocoeeosis in the immunocompetent host: Therapy with oral flueonazole: a report of four eases and a review of the literature [J] . Chest, 2000, 118 (2) : 527 - 534.
6Saag MS, Graybin RJ, Larsen RA, et al. Practice guidelines for the management of eryptococcal disease [J]. Clin Infect Dis, 2000, 30 (4): 710-718.
2Barchiesi F, Cogliati M, Esposto MC, et al. Comparative analysis of pathogenicity of Cryptoeoecus neoformans serotypes A, D and AD in murine cryptococcosis. J Infect,2005,51:10-16.
3Hajjeh RA, Conn LA, Stephens DS, et al. Cryptococcosis: populationbased multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptoeoccal Active Surveillance Group. J Infect Dis, 1999,179:449-454.
4Currie BP, Casadevall A. Estimation of the prevalence of cryptececcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis, 1994,19:1029-1033.
5Mirza SA,Phelan M,Rimland D,et al. The changing epidemiology of cryptoeoecosis :an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis,2003,36:789-794.
6Campbell GD. Primary pulmonary cryptococcosis. Am Rev Respir Dis, 1966,94:236-243.
7Saag MS,Graybill RJ,Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis ,2000,30:710-718.
8Kim Y et al.J Comput Assist Tomogr, 1999; 23(4):622-626
9Won HJ et al. Radiology, 1998; 208(3): 777-782
10Vogl TJ et al. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr, 2000; 172(7) :604-608
